Posted by Michael Wonder on 10 Oct 2018
New drugs: how much are governments paying for innovation?
10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments.
The European healthcare sector is divided over the “actual value” EU governments pay for the authorised and partly public-funded novel drugs, compared to medicines already on the market.
The linkage between the regulatory approval framework and the evidential requirements for innovative medicine is high on the health political agenda. The fine line between the need for pharma innovation, affordability and patients’ safety in practice proves hard to identify.
